Amgen Stock Jumps Despite UK Regulatory Setback for Tavneos

Amgen Inc.'s stock price has increased by 1.53% to $436.45 as of September 1, 2026, with a market capitalization of $236.25 billion.

The rise comes after a UK regulator report stated that the Medicines and Healthcare products Regulatory Agency suspended new-patient use of Tavneos and plans to revoke approval on March 1, 2027.

Despite this setback, Amgen's Q2 numbers remain strong, with revenue of $38.09 billion over the trailing 12 months, diluted EPS of $16.09, and EBITDA of $17.27 billion.

The company's operating margin is 35.55%, while its gross margin stands at 69.52% for Q2 2026.